# Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

> **NCT05323734** · PHASE3 · COMPLETED · sponsor: **Marinus Pharmaceuticals** · enrollment: 129 (actual)

## Conditions studied

- Tuberous Sclerosis Complex

## Interventions

- **DRUG:** Ganaxolone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05323734
- **Lead sponsor:** Marinus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-01
- **Primary completion:** 2024-09-09
- **Final completion:** 2024-10-14
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05323734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05323734, "Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05323734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*